医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Global Virus Network on H7N9 Bird Flu Outbreak

2013年04月20日 AM02:10
このエントリーをはてなブックマークに追加


 

BALTIMORE

As of April 19, 2013, mainland China reported 87 cases of human infection of a new strain of bird influenza, A(H7N9), including 17 deaths. Thus far, the cases are sporadic and have no evidence of human-to-human transmission. According to the Global Virus Network’s Dr. Peter Palese of the Icahn School of Medicine at Mount Sinai, “It is important to note that sporadic human infections with H7 viruses have occurred in the past – this is not a unique situation.”

Dr. Sharon Hrynkow, President of the Global Virus Network (GVN) stated that GVN scientists from China, Japan and the US were sharing data and information in order to assist with efforts to address this outbreak. “The coalition of scientists comprising the Global Virus Network have pledged to work together in outbreak situations as a way to speed knowledge about risk factors, severity of disease and development of interventions. This situation is an example of how the GVN adds value in addressing critical health challenges.”

GVN’s Dr. Yuelong Shu, who is Deputy Director of National Institute for Viral Disease Control and Prevention, China CDC, said, “We will continue to prioritize the public’s health and security and adhere to the requirements of the International Health Regulations (2005) to maintain transparency.”

Dr. Robert Gallo, Co-Founder and Scientific Director of the GVN, lauded China for “the swiftness with which it responded to the epidemic, released information in a timely manner and cooperated with international organizations.”

As we have viral genome sequences of H7N9, GVN is working with Chinese colleagues to obtain information about the pathogenesis of some of the most severe cases from a postmortem examination of fatal cases to better understand the disease. GVN’s Hideki Hasegawa of the National Institutes of Infectious Diseases in Tokyo says, “Some drug resistant mutation was reported, so we would like to know the clinical outcome of the treatment. Additionally, we would like to hear from China about risk factors (age, sex, underlying conditions, etc.) of the severity of the disease which would also help for preparation of vaccine policy.” GVN’s Andrew Pekosz of the Johns Hopkins Bloomberg School of Public Health says we need “to continue rigorous epidemiological studies to detect potential for human-to-human transmission.”

Dr. Shu continued, “GVN’s China-CDC is committed to working with the GVN colleagues to identify the disease etiology characteristics of H7N9 and its epidemic features. We will also work with GVN Centers to collect and analyze domestic and foreign related research progress and results, conduct dynamic risk assessment, and develop prevention control strategies and measures that are driven by the science.”

Frequently Asked Questions on human infection with influenza A(H7N9) virus, China

About Global Virus Network (GVN)

The Global Virus Network (GVN) is a non-profit, 501(C)(3) organization, comprised of leading medical virologists from Argentina, Australia, Belgium, Canada, China, France, Germany, India, Ireland, Israel, Italy, Japan, Netherlands, Russia, South Africa, Spain, Sweden, the United Kingdom and the United States of America. The GVN’s mission is to combat emerging pandemic viral threats through international collaborative research, training the next generation of medical virologists, and advocacy. For more information, please contact Nora Grannell at ngrannell@gvn.org.

CONTACT

Global Virus Network (GVN)
Nora Grannell, 410-706-1966
ngrannell@gvn.org

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表